| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| NBIXNeurocrine Biosciences, Inc. | 13.3B | 133.35 | 40.53 | 24.81% | 15.95% | 14.25% | 4.19% | 0.18 |
| SUPNSupernus Pharmaceuticals, Inc. | 2.88B | 50.26 | 38.08 | 8.94% | -2.8% | -1.82% | 5.94% | 0.03 |
| PTPIPetros Pharmaceuticals, Inc. | 338.98K | 0.01 | -0.00 | -12.2% | -9.68% | -208.53% | ||
| QNTMQuantum BioPharma Ltd. | 26.75M | 6.96 | -0.56 | -379.78% | 0.08 | |||
| AYTUAytu BioPharma, Inc. | 28.12M | 2.76 | -1.28 | 1.84% | -20.52% | -56.41% | 1.21 | |
| AQSTAquestive Therapeutics, Inc. | 407.49M | 3.34 | -6.55 | 13.8% | -158.95% | |||
| AVDLAvadel Pharmaceuticals plc | 2.11B | 21.48 | -42.12 | 5.05% | -0.11% | -0.28% | 0.02 | |
| RGCRegencell Bioscience Holdings Limited | 14.86B | 30.06 | -3455.17 | -67.02% | 0.01 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 173.21M | 150.25M | 172.74M | 103.27M | 59.22M | 22.33M | 0 | 0 | 27.96M | 169.12M |
| Revenue Growth % | 10.72% | -0.13% | 0.15% | -0.4% | -0.43% | -0.62% | -1% | - | - | 5.05% |
| Cost of Goods Sold | 10.92M | 13.25M | 16.3M | 17.52M | 12.13M | 5.74M | 0 | 0 | 846K | 15.28M |
| COGS % of Revenue | 0.06% | 0.09% | 0.09% | 0.17% | 0.2% | 0.26% | - | - | 0.03% | 0.09% |
| Gross Profit | 162.29M | 137M | 156.44M | 85.75M | 47.09M | 16.59M | 0 | 0 | 27.12M | 153.84M |
| Gross Margin % | 0.94% | 0.91% | 0.91% | 0.83% | 0.8% | 0.74% | - | - | 0.97% | 0.91% |
| Gross Profit Growth % | 13.25% | -0.16% | 0.14% | -0.45% | -0.45% | -0.65% | -1% | - | - | 4.67% |
| Operating Expenses | 59.88M | 92.68M | 96.74M | 146.31M | 71.2M | 10.78M | 85.55M | 98.56M | 164.97M | 196.24M |
| OpEx % of Revenue | 0.35% | 0.62% | 0.56% | 1.42% | 1.2% | 0.48% | - | - | 5.9% | 1.16% |
| Selling, General & Admin | 21.71M | 44.18M | 58.86M | 100.36M | 30.18M | 32.41M | 68.5M | 74.52M | 151.71M | 181.04M |
| SG&A % of Revenue | 0.13% | 0.29% | 0.34% | 0.97% | 0.51% | 1.45% | - | - | 5.43% | 1.07% |
| Research & Development | 25.61M | 34.61M | 34.22M | 39.33M | 32.92M | 20.44M | 17.1M | 20.7M | 13.26M | 15.2M |
| R&D % of Revenue | 0.15% | 0.23% | 0.2% | 0.38% | 0.56% | 0.92% | - | - | 0.47% | 0.09% |
| Other Operating Expenses | 0 | -6.55M | 2.08M | 1.9M | 8.1M | -42.07M | -53K | 3.35M | 0 | 0 |
| Operating Income | 71.45M | -4.96M | 88.3M | -104.93M | -24.11M | 5.82M | -85.55M | -98.56M | -137.85M | -42.4M |
| Operating Margin % | 0.41% | -0.03% | 0.51% | -1.02% | -0.41% | 0.26% | - | - | -4.93% | -0.25% |
| Operating Income Growth % | 1.76% | -1.07% | 18.78% | -2.19% | 0.77% | 1.24% | -15.71% | -0.15% | -0.4% | 0.69% |
| EBITDA | 84.58M | 9.52M | 93.18M | -97.5M | -21.63M | 7.5M | -84.73M | -97.07M | -136.08M | -39.72M |
| EBITDA Margin % | 0.49% | 0.06% | 0.54% | -0.94% | -0.37% | 0.34% | - | - | -4.87% | -0.23% |
| EBITDA Growth % | 2.06% | -0.89% | 8.78% | -2.05% | 0.78% | 1.35% | -12.29% | -0.15% | -0.4% | 0.71% |
| D&A (Non-Cash Add-back) | 13.13M | 14.49M | 4.88M | 7.43M | 2.49M | 1.69M | 815K | 1.49M | 1.77M | 2.68M |
| EBIT | 77.7M | -8.76M | 61.01M | -102.58M | -26.1M | 7.91M | -83.2M | -99.1M | -150.89M | -38.25M |
| Net Interest Income | 0 | -963K | -1.05M | -10.62M | -12.48M | -12.99M | -9.94M | -12.34M | -9.89M | -10.83M |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 6.3M | 963K | 1.05M | 10.62M | 12.48M | 12.99M | 9.94M | 12.34M | 9.89M | 10.83M |
| Other Income/Expense | 6.26M | -4.75M | 3.15M | -8.27M | -14.47M | -10.9M | -7.6M | -12.88M | -22.93M | -6.68M |
| Pretax Income | 78.39M | -9.72M | 91.47M | -113.2M | -38.58M | -5.08M | -93.14M | -111.44M | -160.78M | -49.08M |
| Pretax Margin % | 0.45% | -0.06% | 0.53% | -1.1% | -0.65% | -0.23% | - | - | -5.75% | -0.29% |
| Income Tax | 37.73M | 31.56M | 24.21M | -17.89M | -5.36M | -12.11M | -15.82M | 26.02M | -501K | -247K |
| Effective Tax Rate % | 0.52% | 4.25% | 0.74% | 0.84% | 0.86% | -1.38% | 0.83% | 1.23% | 1% | 0.99% |
| Net Income | 40.66M | -41.28M | 67.25M | -95.3M | -33.23M | 7.03M | -77.33M | -137.46M | -160.28M | -48.83M |
| Net Margin % | 0.23% | -0.27% | 0.39% | -0.92% | -0.56% | 0.31% | - | - | -5.73% | -0.29% |
| Net Income Growth % | 1.48% | -2.02% | 2.63% | -2.42% | 0.65% | 1.21% | -12% | -0.78% | -0.17% | 0.7% |
| Net Income (Continuing) | 41.8M | -41.28M | 68.27M | -95.3M | -33.23M | 7.03M | -77.33M | -137.46M | -160.28M | -48.83M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 0.93 | -1.00 | 1.61 | -2.55 | -0.89 | 0.13 | -1.32 | -2.29 | -2.00 | -0.51 |
| EPS Growth % | 1.4% | -2.08% | 2.61% | -2.58% | 0.65% | 1.15% | -11.15% | -0.73% | 0.13% | 0.74% |
| EPS (Basic) | 1.00 | -1.00 | 1.66 | -2.55 | -0.89 | 0.13 | -1.32 | -2.29 | -2.00 | -0.51 |
| Diluted Shares Outstanding | 43.62M | 41.25M | 41.77M | 37.33M | 37.4M | 54.94M | 58.53M | 60.09M | 80.17M | 95.14M |
| Basic Shares Outstanding | 40.58M | 41.25M | 40.47M | 37.33M | 37.4M | 53M | 58.53M | 60.09M | 80.17M | 95.14M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 166.31M | 181.19M | 123.95M | 124.85M | 82.38M | 263.45M | 192.49M | 100.84M | 134.2M | 134.21M |
| Cash & Short-Term Investments | 144.8M | 154.19M | 94.08M | 99.92M | 64.16M | 221.4M | 157.22M | 96.5M | 105.11M | 73.78M |
| Cash Only | 65.06M | 39.22M | 16.56M | 9.32M | 9.77M | 71.72M | 50.71M | 73.98M | 31.17M | 51.37M |
| Short-Term Investments | 79.74M | 114.98M | 77.51M | 90.59M | 54.38M | 149.68M | 106.51M | 22.52M | 73.94M | 22.41M |
| Accounts Receivable | 7.49M | 17.84M | 16.51M | 13.91M | 11.97M | 38.78M | 31.54M | 2.25M | 12.1M | 34.1M |
| Days Sales Outstanding | 15.78 | 43.34 | 34.88 | 49.17 | 73.81 | 633.81 | - | - | 157.98 | 73.59 |
| Inventory | 4.16M | 3.26M | 6.16M | 4.77M | 3.57M | 0 | 0 | 0 | 10.38M | 20.3M |
| Days Inventory Outstanding | 138.87 | 89.76 | 137.86 | 99.4 | 107.47 | - | - | - | 4.48K | 484.96 |
| Other Current Assets | 7.53M | 2.45M | 128K | 4.11M | 561K | 2.25M | 550K | 573K | 2.23M | 882K |
| Total Non-Current Assets | 48.67M | 64.3M | 128.15M | 65.45M | 69.06M | 48.18M | 54.77M | 31.94M | 30.5M | 30.03M |
| Property, Plant & Equipment | 2.62M | 3.32M | 3M | 7.8M | 4.16M | 2.96M | 11.49M | 13.24M | 13.08M | 12.86M |
| Fixed Asset Turnover | 66.21x | 45.25x | 57.56x | 13.23x | 14.25x | 7.54x | - | - | 2.14x | 13.16x |
| Goodwill | 18.49M | 18.49M | 18.49M | 18.49M | 18.49M | 16.84M | 16.84M | 16.84M | 16.84M | 16.84M |
| Intangible Assets | 15.82M | 22.84M | 92.29M | 1.63M | 813K | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 1.77M | 1.4M | 8.75M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 158K | 7.53M | 9.1M | 5.75M | 16.17M | 10.13M | 2.33M | 1.87M | 579K | 337K |
| Total Assets | 214.98M | 245.48M | 252.11M | 190.3M | 151.44M | 311.64M | 247.26M | 132.78M | 164.7M | 164.24M |
| Asset Turnover | 0.81x | 0.61x | 0.69x | 0.54x | 0.39x | 0.07x | - | - | 0.17x | 1.03x |
| Asset Growth % | 0.23% | 0.14% | 0.03% | -0.25% | -0.2% | 1.06% | -0.21% | -0.46% | 0.24% | -0% |
| Total Current Liabilities | 48.79M | 62.42M | 86.18M | 38.38M | 35.98M | 15.11M | 21M | 55.79M | 36.85M | 48.83M |
| Accounts Payable | 5.05M | 7.11M | 7.48M | 3.5M | 6.1M | 2.93M | 7.68M | 7.89M | 11.43M | 7.33M |
| Days Payables Outstanding | 168.71 | 195.75 | 167.42 | 73 | 183.63 | 186.5 | - | - | 4.93K | 175.08 |
| Short-Term Debt | 434K | 268K | 111K | 106K | 645K | 474K | 0 | 37.67M | 0 | 0 |
| Deferred Revenue (Current) | 1000K | 1000K | 1000K | 114K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 32.43M | 48.33M | 72.17M | 29.74M | 24.7M | 10M | 3.52M | 1.91M | 11.8M | 21.01M |
| Current Ratio | 3.41x | 2.90x | 1.44x | 3.25x | 2.29x | 17.44x | 9.17x | 1.81x | 3.64x | 2.75x |
| Quick Ratio | 3.32x | 2.85x | 1.37x | 3.13x | 2.19x | 17.44x | 9.17x | 1.81x | 3.36x | 2.33x |
| Cash Conversion Cycle | -14.07 | -62.65 | 5.33 | 75.57 | -2.35 | - | - | - | -296.33 | 383.47 |
| Total Non-Current Liabilities | 98.32M | 140.99M | 81.37M | 149.14M | 144.65M | 134.26M | 148.02M | 98.14M | 40.1M | 41.55M |
| Long-Term Debt | 684K | 547K | 156K | 115.73M | 121.69M | 128.21M | 142.4M | 91.61M | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 2.32M | 1.84M | 1.71M | 780K | 1.69M | 1.12M |
| Deferred Tax Liabilities | 1.35M | 134.26M | 72.28M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 94.37M | 140.44M | 81M | 33.4M | 20.65M | 4.21M | 3.92M | 5.74M | 38.41M | 40.43M |
| Total Liabilities | 147.11M | 203.41M | 167.54M | 187.52M | 180.63M | 149.37M | 169.02M | 153.93M | 76.96M | 90.39M |
| Total Debt | 1.12M | 815K | 267K | 115.84M | 124.65M | 130.52M | 145M | 131.02M | 2.62M | 1.7M |
| Net Debt | -63.95M | -38.4M | -16.3M | 106.52M | 114.88M | 58.8M | 94.3M | 57.04M | -28.54M | -49.67M |
| Debt / Equity | 0.02x | 0.02x | 0.00x | 41.67x | - | 0.80x | 1.85x | - | 0.03x | 0.02x |
| Debt / EBITDA | 0.01x | 0.09x | 0.00x | - | - | 17.39x | - | - | - | - |
| Net Debt / EBITDA | -0.76x | -4.03x | -0.17x | - | - | 7.84x | - | - | - | - |
| Interest Coverage | 11.34x | -5.16x | 83.94x | -9.88x | -1.93x | 0.45x | -8.60x | -7.99x | -13.94x | -3.91x |
| Total Equity | 67.86M | 42.07M | 84.56M | 2.78M | -29.2M | 162.27M | 78.24M | -21.14M | 87.74M | 73.85M |
| Equity Growth % | 1.73% | -0.38% | 1.01% | -0.97% | -11.5% | 6.56% | -0.52% | -1.27% | 5.15% | -0.16% |
| Book Value per Share | 1.56 | 1.02 | 2.02 | 0.07 | -0.78 | 2.95 | 1.34 | -0.35 | 1.09 | 0.78 |
| Total Shareholders' Equity | 67.86M | 42.07M | 84.56M | 2.78M | -29.2M | 162.27M | 78.24M | -21.14M | 87.74M | 73.85M |
| Common Stock | 6.33M | 414K | 414K | 427K | 429K | 583K | 586K | 628K | 898K | 965K |
| Retained Earnings | -279.79M | -319.8M | -263.7M | -357.99M | -391.21M | -384.19M | -447.76M | -585.22M | -745.5M | -794.33M |
| Treasury Stock | 0 | 0 | -22.36M | -50M | -50M | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -22.66M | -23.57M | -23.27M | -23.42M | -22.81M | -21.05M | -23.94M | -26.34M | -23.17M | -24.58M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 84.29M | 18.9M | 16.66M | -82.72M | -38.33M | -48.73M | -77.31M | -70.3M | -128.51M | -46.91M |
| Operating CF Margin % | 0.49% | 0.13% | 0.1% | -0.8% | -0.65% | -2.18% | - | - | -4.6% | -0.28% |
| Operating CF Growth % | 8.94% | -0.78% | -0.12% | -5.96% | 0.54% | -0.27% | -0.59% | 0.09% | -0.83% | 0.63% |
| Net Income | 40.66M | -41.28M | 67.25M | -95.3M | -33.23M | 7.03M | -77.33M | -137.46M | -160.28M | -48.83M |
| Depreciation & Amortization | 13.13M | 14.49M | 4.88M | 7.43M | 2.49M | 1.69M | 815K | 1.49M | 1.77M | 2.68M |
| Stock-Based Compensation | 7.74M | 14.68M | 8.07M | 7.85M | 519K | 3M | 8.87M | 7.01M | 15.81M | 20.39M |
| Deferred Taxes | 1.42M | -4M | 3.56M | -19.15M | -6.33M | -7.43M | -15.67M | 26.02M | 0 | 0 |
| Other Non-Cash Items | 26.15M | 33.7M | -69.53M | 28.17M | -4.02M | -44.88M | 2.3M | 8.09M | 17.19M | -828K |
| Working Capital Changes | -4.81M | 1.31M | 2.42M | -11.71M | 2.25M | -8.13M | 3.69M | 24.54M | -3M | -20.32M |
| Change in Receivables | -8.11M | -10.05M | 3.08M | 3.45M | 1.46M | 10.49M | 2.8M | 30K | -10.22M | -21.99M |
| Change in Inventory | 2.55M | 1.83M | -2.9M | 711K | 1.16M | -1.35M | 0 | -30K | -9.53M | -9.22M |
| Change in Payables | -3.89M | -434K | 596K | -2.03M | 4.64M | -2.79M | 4.23M | -3.11M | 1.54M | -4.09M |
| Cash from Investing | -31.73M | -36.63M | -15.7M | -36.98M | 38.72M | -69.72M | 56.93M | 79.7M | -50.09M | 51.78M |
| Capital Expenditures | -1.63M | -1.2M | -53.7M | -20.18M | -29K | -98K | -26K | -716K | 0 | 0 |
| CapEx % of Revenue | 0.01% | 0.01% | 0.31% | 0.2% | 0% | 0% | - | - | - | - |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -779K | -36.06M | -53.11M | -20M | 154K | 0 | 0 | 80.41M | 0 | 0 |
| Cash from Financing | -23.75M | -7.95M | -23.32M | 112.66M | -27K | 179.68M | 263K | 14.54M | 135.34M | 15.97M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | -25.83M | -8.39M | -1.36M | -4.03M | -145K | 0 | 263K | -10.78M | 27.94M | 6.72M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | 82.66M | 17.7M | -37.04M | -102.89M | -38.35M | -48.83M | -77.34M | -71.02M | -128.51M | -46.91M |
| FCF Margin % | 0.48% | 0.12% | -0.21% | -1% | -0.65% | -2.19% | - | - | -4.6% | -0.28% |
| FCF Growth % | 7.7% | -0.79% | -3.09% | -1.78% | 0.63% | -0.27% | -0.58% | 0.08% | -0.81% | 0.63% |
| FCF per Share | 1.90 | 0.43 | -0.89 | -2.76 | -1.03 | -0.89 | -1.32 | -1.18 | -1.60 | -0.49 |
| FCF Conversion (FCF/Net Income) | 2.07x | -0.46x | 0.25x | 0.87x | 1.15x | -6.93x | 1.00x | 0.51x | 0.80x | 0.96x |
| Interest Paid | 4.74M | 788K | 1.05M | 3.36M | 6.47M | 6.47M | 6.47M | 0 | 0 | 0 |
| Taxes Paid | 42.12M | 27.18M | 19.14M | 776K | 140K | 0 | 76K | 0 | 0 | 0 |
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | 87.66% | -75.09% | 106.22% | -218.23% | - | 10.56% | -64.3% | -481.49% | -481.35% | -60.44% |
| Return on Invested Capital (ROIC) | 99.66% | -98.15% | 184.12% | -88.64% | -18.55% | 2.84% | -32.6% | -70.93% | -217.45% | -76.28% |
| Gross Margin | 93.69% | 91.18% | 90.56% | 83.04% | 79.52% | 74.29% | - | - | 96.97% | 90.97% |
| Net Margin | 23.47% | -27.47% | 38.93% | -92.29% | -56.11% | 31.47% | - | - | -573.17% | -28.87% |
| Debt / Equity | 0.02x | 0.02x | 0.00x | 41.67x | - | 0.80x | 1.85x | - | 0.03x | 0.02x |
| Interest Coverage | 11.34x | -5.16x | 83.94x | -9.88x | -1.93x | 0.45x | -8.60x | -7.99x | -13.94x | -3.91x |
| FCF Conversion | 2.07x | -0.46x | 0.25x | 0.87x | 1.15x | -6.93x | 1.00x | 0.51x | 0.80x | 0.96x |
| Revenue Growth | 1072.31% | -13.26% | 14.97% | -40.22% | -42.66% | -62.28% | -100% | - | - | 504.79% |
| 2012 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Reportable | - | - | - | - | - | - | - | - | 169.12M |
| Reportable Growth | - | - | - | - | - | - | - | - | - |
| Vazculep | - | - | 20.15M | 39.8M | 38.19M | - | - | 10.43M | - |
| Vazculep Growth | - | - | - | 97.49% | -4.04% | - | - | - | - |
| Akovaz | - | - | - | 16.83M | 80.62M | - | - | 9.54M | - |
| Akovaz Growth | - | - | - | - | 378.98% | - | - | - | - |
| Bloxiverz | - | 33M | 150.28M | 82.9M | 45.6M | - | - | 2.2M | - |
| Bloxiverz Growth | - | - | 355.40% | -44.84% | -45.00% | - | - | - | - |
| Other Products | - | - | 108K | 7.7M | 8.44M | - | - | 159K | - |
| Other Products Growth | - | - | - | 7028.70% | 9.64% | - | - | - | - |
| License | - | - | - | - | - | - | - | - | - |
| License Growth | - | - | - | - | - | - | - | - | - |
| Wholesaler Customer | - | - | - | - | - | 101.42M | 59.22M | - | - |
| Wholesaler Customer Growth | - | - | - | - | - | - | -41.62% | - | - |
| Dextroamphetamine | - | - | 1.95M | - | - | - | - | - | - |
| Dextroamphetamine Growth | - | - | - | - | - | - | - | - | - |
| 2012 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| UNITED STATES | - | - | 172.38M | 147.28M | 172.84M | - | 59.22M | 22.33M | - |
| UNITED STATES Growth | - | - | - | -14.56% | 17.35% | - | - | -62.28% | - |
| IRELAND | - | - | 741K | 2.96M | 404K | 1.85M | - | - | - |
| IRELAND Growth | - | - | - | 299.87% | -86.37% | 356.93% | - | - | - |
| FRANCE | - | - | 89K | - | - | - | - | - | - |
| FRANCE Growth | - | - | - | - | - | - | - | - | - |
| Usa | 3.89M | 14.3M | - | - | - | - | - | - | - |
| Usa Growth | - | 267.66% | - | - | - | - | - | - | - |
| Europe | 3.31M | 473K | - | - | - | - | - | - | - |
| Europe Growth | - | -85.72% | - | - | - | - | - | - | - |
| United Kingdom and Ireland | 15.97M | - | - | - | - | - | - | - | - |
| United Kingdom and Ireland Growth | - | - | - | - | - | - | - | - | - |
| France | 2.93M | - | - | - | - | - | - | - | - |
| France Growth | - | - | - | - | - | - | - | - | - |
Avadel Pharmaceuticals plc (AVDL) reported $248.5M in revenue for fiscal year 2024. This represents a 662% increase from $32.6M in 2011.
Avadel Pharmaceuticals plc (AVDL) grew revenue by 504.8% over the past year. This is strong growth.
Avadel Pharmaceuticals plc (AVDL) reported a net loss of $0.3M for fiscal year 2024.
Avadel Pharmaceuticals plc (AVDL) has a return on equity (ROE) of -60.4%. Negative ROE indicates the company is unprofitable.
Avadel Pharmaceuticals plc (AVDL) generated $35.4M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.